Market research
ETON Eton Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- 162.74
- Analyst target
- 71
- Dividend yield
- Not available
- Beta
- 0.87
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- US29772L1089
- Market cap
- 2B
- P/E ratio
- 162.74
- Analyst target
- 71
- Dividend yield
- Not available
- Beta
- 0.87
About
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ETON discussion.
5 years, 4 months ago
Eton Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 27.9% below its 200 day moving average.
From a valuation standpoint, the stock is 196.0% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 3965.0.
Eton Pharmaceuticals, Inc's total revenue sank by 82.4% to $81K since the same quarter in the previous year.
Its net income has dropped by 185.1% to $-8M since the same quarter in the previous year.
Finally, its free cash flow fell by 56.0% to $-7M since the same quarter in the previous year.
Based on the above factors, Eton Pharmaceuticals, Inc gets an overall score of 0/5.